| pubmed-article:11227682 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C0238124 | lld:lifeskim |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C0024453 | lld:lifeskim |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C0037633 | lld:lifeskim |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C1382100 | lld:lifeskim |
| pubmed-article:11227682 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:11227682 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11227682 | pubmed:dateCreated | 2001-2-28 | lld:pubmed |
| pubmed-article:11227682 | pubmed:abstractText | Twenty-nine patients with necrotizing fasciitis who were treated with 5% mafenide acetate solution (MAS) as an adjunct after grafting were compared with 45 patients treated without MAS. Statistical analysis of differences was obtained through P values by chi2 testing. The MAS+ (M) and MAS- (C) groups were similar in percent skin deficit (M = 7.5%; C = 9.8%), with the extremity being the most common area of infection. Streptococcus was the most common single organism but polymicrobial infections were the most prevalent (M = 48%; C = 58%). Patients with necrotizing fasciitis treated with MAS had fewer debridements per patient (M = 3.7; C = 5.4), fewer closure procedures (average per patient: M = 1.2; C = 1.73) and a higher percent of first-time closures (83 vs 59%; chi2 = 4.26; P = 0.039). There is a trend toward a lower mortality rate (3.4 vs 13%; chi2 = 2.00; P = 0.158). We conclude that MAS is a useful adjunct in necrotizing fasciitis wound care protocols. | lld:pubmed |
| pubmed-article:11227682 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11227682 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11227682 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11227682 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11227682 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11227682 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11227682 | pubmed:issn | 0273-8481 | lld:pubmed |
| pubmed-article:11227682 | pubmed:author | pubmed-author:ReillyD ADA | lld:pubmed |
| pubmed-article:11227682 | pubmed:author | pubmed-author:GarnerW LWL | lld:pubmed |
| pubmed-article:11227682 | pubmed:author | pubmed-author:DoughertyW... | lld:pubmed |
| pubmed-article:11227682 | pubmed:author | pubmed-author:HeinleE CEC | lld:pubmed |
| pubmed-article:11227682 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11227682 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:11227682 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11227682 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11227682 | pubmed:pagination | 35-40 | lld:pubmed |
| pubmed-article:11227682 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:meshHeading | pubmed-meshheading:11227682... | lld:pubmed |
| pubmed-article:11227682 | pubmed:articleTitle | The use of 5% mafenide acetate solution in the postgraft treatment of necrotizing fasciitis. | lld:pubmed |
| pubmed-article:11227682 | pubmed:affiliation | University of Southern California School of Medicine, Los Angeles, USA. | lld:pubmed |
| pubmed-article:11227682 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11227682 | pubmed:publicationType | Comparative Study | lld:pubmed |
